Lilly's Obesity Pill Got 1,390 Prescriptions in a Week. Wall Street Panicked.

Lilly itself flagged that early prescription data from IQVIA (the tracking firm) likely undercounts actual scripts because not all pharmacies are captured immediately after launch. The company recommended watching trends over time rather than fixating on week one. By week two, Foundayo prescriptions had already climbed to 3,707, nearly tripling.

J.P. Morgan analyst Chris Schott reportedly views the slower start as expected, given Wegovy's head start and established brand recognition. He advised against overinterpreting the early numbers.

History Says: Relax (Maybe)

Blockbuster drugs almost never explode out of the gate. Wegovy itself, approved in June 2021, faced immediate supply shortages that limited how many patients could actually get it. And Saxenda, the first obesity-approved GLP-1 from 2014, basically flatlined for seven years before the broader GLP-1 wave lifted all boats in 2021.

The pattern is consistent: demand builds, supply catches up, insurance coverage expands, and then the hockey stick appears. Lilly seems to know this playbook well; the company pre-built $1.5 billion in Foundayo inventory to avoid the shortage headaches that plagued earlier launches.

The Real Competitive Battle

The more interesting story isn't Foundayo's rocky first week. It's the emerging pill-versus-pill war between Lilly and Novo.

Novo published an analysis called ORION in April 2026, claiming oral Wegovy delivers about 3% greater weight loss than Foundayo. Lilly disputes the methodology, and no independent head-to-head trial exists at obesity doses. So for now, both sides are essentially arguing over whose homework is more accurate without a teacher to grade it.

Foundayo does have a practical advantage, though. Patients can take it anytime, with or without food. Oral Wegovy requires an empty stomach in the morning, which is the kind of daily inconvenience that quietly drives people to switch medications over time. Foundayo is also a small molecule rather than a peptide, which makes it significantly easier to manufacture at scale.

Pricing is nearly identical. Foundayo starts at $149 per month for self-pay patients, drops to $25 per month with commercial insurance, and costs no more than $50 per month for Medicare beneficiaries.

What the Smart Money Is Watching

Lilly reports earnings on April 30, and that call will be the real test.

But the stock is down 13-18% year-to-date, weighed down by Foundayo jitters, concerns about Trump-era tariff impacts on drug pricing, and 2026 revenue guidance ($80-83 billion) that left some investors wanting more.

The Bigger Picture

The oral GLP-1 market is still in its infancy. Only about mid-single digits of eligible obesity patients are currently on any GLP-1 treatment. Projections suggest 25 million Americans could be taking these drugs by 2030, up from roughly 10 million today. The global GLP-1 market is expected to exceed $170 billion by 2033.

More oral GLP-1 compounds are in Phase 2 or Phase 3 trials behind Foundayo and oral Wegovy. This category is about to get very crowded, which means the real winners will be determined by convenience, side effects, and price, not first-week prescription counts.

Lilly's 1,390 prescriptions make for a spicy headline. But the obesity drug race is a marathon, not a sprint. And Lilly has run this race before with Zepbound, turning a slow start into $36.5 billion in combined GLP-1 sales last year. Writing them off after seven days would be like benching a quarterback after one bad drive in the first quarter.

The game is far from over.

UCB Just Bet $1.15 Billion That Brain Cells Can Cure Seizures

UCB is paying up to $1.15 billion for Neurona Therapeutics and its brain cell therapy that cut seizures by 92% in early trials. It's one of the boldest bets yet that cell therapy can work far beyond cancer.